CPC A61K 31/57 (2013.01) [A61B 17/435 (2013.01); A61K 9/0019 (2013.01); A61K 9/0034 (2013.01); A61K 31/404 (2013.01); A61K 31/4045 (2013.01); A61K 31/565 (2013.01); A61K 38/095 (2019.01); A61K 38/12 (2013.01); A61K 45/06 (2013.01)] | 11 Claims |
1. A method for treating a female subject undergoing embryo transfer comprising administering to the female subject an oxytocin receptor antagonist formulated as a sustained or delayed release formulation, such that an effect of the antagonist overlaps with a receptive endometrium stage in said female subject and transferring a blastocyst-stage embryo into a uterus, a uterine cavity, or fallopian tubes of the female subject.
|